As shown in Figure 4E, the biomarker panel exhibited better diagnostic performance than AFP alone in differentiating MetS(+) HCC patients from MetS individuals (AUC 0.87, sensitivity 78.79% and specificity 91.00% at the optimal cut-off point) (Figure 4E and Table 2). The gene discussed is AFP; the disease is hepatocellular carcinoma.